Healthcare
Orchestra BioMed Holdings, Inc.(OBIO)
Live Price
Offline$3.99
+3.10% today
1Y Change
+29.13%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $230.00M
- Revenue Growth
- +1169.2%
- EPS Growth
- +33.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Orchestra BioMed Holdings, Inc. (OBIO) is a Healthcare stock with a market cap of $230.00M and listed on NASDAQ. The stock last traded around $3.99 and up 29.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +1169.2%, EPS growth of +33.1%, a dividend yield of 0.0%. What stands out right now is revenue +1169.2%, EPS +33.1%, free cash flow +2.7% with operating margin -154.7% and ROIC -52.4%. Valuation sits in the middle of the pack at price/sales 6.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines OBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1169.2% vs +7.6% peer median
Operating Margin
Below sector median
-154.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1169.2% and EPS at +33.1%, with operating margin around -154.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.7% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +3.8% | +1.8% | +3.1% |
2026 Mar 12, 2026 | +168.4% | -4.1% | +5.9% | -5.7% |
2025 Nov 10, 2025 | -5.3% | +8.5% | +9.3% | +11.1% |
Benchmark Edge
OBIO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OBIO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OBIO Max Drawdown
-34.77%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OBIO and SPY.
Company Overview
Orchestra BioMed Holdings, Inc.
NASDAQ Global Market
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
- Leadership
- David Hochman
- IPO Date
- Aug 4, 2020
- Employees
- 70
- Street Address
- 150 Union Square Drive
- Mailing
- New Hope, PA, 18938
- Region
- New Hope, PA, US
- Reporting Currency
- USD
- Investor Line
- 215 862 5797
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.9
- Price/Book
- 2.4
Growth
- Revenue
- +1169.2%
- EPS
- +33.1%
- Free Cash Flow
- +2.7%
Profitability
- Gross Margin
- 99.4%
- Operating Margin
- -154.7%
- Net Margin
- -157.4%
- ROE
- -169.6%
- ROIC
- -52.4%
Balance Sheet
- Debt/Equity
- 0.51
- Current Ratio
- 6.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.